Islam Rafiqul, Kar Sumit, Islam Clarinda, Farmen Raymond
Celerion, Inc., Global Bioanalytical Services, 621 Rose Street, Lincoln, NE 68502 USA.
Somru BioScience, Inc., Innovation Way, BioCommons Research Park, Charlottetown Prince Edward Island, C1E 0B7 Canada.
Bioanalysis. 2018 Jun 1;10(12):945-955. doi: 10.4155/bio-2017-0254.
There has been an increased use of commercial kits for biomarker measurement, commensurate with the increased demand for biomarkers in drug development. However, in most cases these kits do not meet the quality attributes for use in regulated environment. The process for adaptation of these kits can be frustrating, time consuming and resource intensive. In addition, a lack of harmonized guidance for the validation of biomarker poses a significant challenge in the adaptation of kits in a regulated environment. The purpose of this perspective is to propose a tiered approach to commercial drug development kits with clearly defined quality attributes and to demonstrate how these kits can be adapted to perform analytical validation in a regulated environment.
随着药物研发中对生物标志物需求的增加,用于生物标志物测量的商业试剂盒的使用也有所增加。然而,在大多数情况下,这些试剂盒不符合在受监管环境中使用的质量属性。适配这些试剂盒的过程可能令人沮丧、耗时且资源密集。此外,缺乏关于生物标志物验证的统一指南,这在受监管环境中适配试剂盒时构成了重大挑战。本观点文章的目的是提出一种针对商业药物研发试剂盒的分层方法,明确界定质量属性,并展示如何使这些试剂盒在受监管环境中进行分析验证。